Pharmeasy Limited Unlisted Shares (PharmEasy)
-22.72 % 1 MAbout Pharmeasy Limited Unlisted Shares (PharmEasy)
A Comprehensive Overview of Price & Journey
Understanding Pharmeasy Limited Unlisted Shares (PharmEasy) Inception and Growth
Pharmeasy Limited Unlisted Shares (PharmEasy) is an unlisted company trading in the private market. Unlike listed companies, the valuation and share price of unlisted or Pre-IPO companies are determined via negotiation and demand & supply. Pharmeasy Limited Unlisted Shares (PharmEasy) are unlisted shares.
Investors looking for diversification of their portfolio should carefully analyze Pharmeasy Limited Unlisted Shares (PharmEasy) unlisted share price, valuation, and research report for the latest year. This is the comprehensive coverage of Pharmeasy Limited Unlisted Shares (PharmEasy), an unlisted share that answers simple questions of investors, such as how to buy unlisted/pre-IPO shares of Pharmeasy Limited Unlisted Shares (PharmEasy), what Pharmeasy Limited Unlisted Shares (PharmEasy) do, and How PharmEasy Unlisted Share Price (PharmEasy) have performed in recent years.
API Holdings Limited, formerly known as API Holdings Private Limited, is the parent company of PharmEasy Unlisted Share Price, one of India's leading digital healthcare platforms. Incorporated on 31 March 2019, the company has built a strong presence across online pharmacy, diagnostics, teleconsultation, and healthcare services.
PharmEasy has transitioned from a company that only offered online medicine delivery to a complete digital healthcare ecosystem. Today, customers can easily order medicines, book diagnostic tests, and consult doctors online as well as access a wide range of healthcare products through a single platform. This growth has made PharmEasy Share one of the most closely tracked opportunities in India's private market.
The company operates through multiple healthcare verticals, including pharmaceutical and healthcare product sales, diagnostic services, teleconsultations, and digital health solutions, which is how they have created a very strong brand reputation and have attracted the attention of millions of customers throughout India.
Investor interest in PharmEasy unlisted share price remains strong, as many market participants continue to follow the company's progress and future listing plans. With ongoing business restructuring and operational improvements, expectations around a future PharmEasy IPO continue to attract attention.
SHOW MORE...
Pharmeasy Limited Unlisted Shares (PharmEasy) is an unlisted company trading in the private market. Unlike listed companies, the valuation and share price of unlisted or Pre-IPO companies are determined via negotiation and demand & supply. Pharmeasy Limited Unlisted Shares (PharmEasy) are unlisted shares.
Investors looking for diversification of their portfolio should carefully analyze Pharmeasy Limited Unlisted Shares (PharmEasy) unlisted share price, valuation, and research report for the latest year. This is the comprehensive coverage of Pharmeasy Limited Unlisted Shares (PharmEasy), an unlisted share that answers simple questions of investors, such as how to buy unlisted/pre-IPO shares of Pharmeasy Limited Unlisted Shares (PharmEasy), what Pharmeasy Limited Unlisted Shares (PharmEasy) do, and How PharmEasy Unlisted Share Price (PharmEasy) have performed in recent years.
API Holdings Limited, formerly known as API Holdings Private Limited, is the parent company of PharmEasy Unlisted Share Price, one of India's leading digital healthcare platforms. Incorporated on 31 March 2019, the company has built a strong presence across online pharmacy, diagnostics, teleconsultation, and healthcare services.
PharmEasy has transitioned from a company that only offered online medicine delivery to a complete digital healthcare ecosystem. Today, customers can easily order medicines, book diagnostic tests, and consult doctors online as well as access a wide range of healthcare products through a single platform. This growth has made PharmEasy Share one of the most closely tracked opportunities in India's private market.
The company operates through multiple healthcare verticals, including pharmaceutical and healthcare product sales, diagnostic services, teleconsultations, and digital health solutions, which is how they have created a very strong brand reputation and have attracted the attention of millions of customers throughout India.
Investor interest in PharmEasy unlisted share price remains strong, as many market participants continue to follow the company's progress and future listing plans. With ongoing business restructuring and operational improvements, expectations around a future PharmEasy IPO continue to attract attention.
About Pharmeasy Limited Unlisted Shares (PharmEasy)
IPO Details, Price movement
PharmEasy Board of Directors
| Vineet Rai | Independent Director |
| Subramaniam Somasundaram | Independent Director |
| Jaydeep Dahyalal Tank | Independent Director |
| Aditya Puri | Professional Director |
| Deepak Calian Vaidya | Independent Director |
| Ankur Nand Thadani | Professional Director |
| Ashutosh Sharma | Professional Director |
| Siddharth Bhaskar Shah | Managing Director |
| Dhaval Shah | Whole-Time Director |
| Dovaldas Buzinskas | Professional Director |
| Hardik Kishor Dedhia | Whole-Time Director |
| Ranjan Ramdas Pai | Professional Director |
| Shyam Powar | Professional Director |
PharmEasy Unlisted Share Price
The PharmEasy unlisted share price is updated regularly on our website. Investors looking to track the latest market activity, valuation changes, and transaction trends can visit our platform for all the latest updates.
Why Investors Are Interested in PharmEasy Share
PharmEasy has become one of India's most recognized health-tech companies by combining healthcare services and technology on a single platform. Several factors continue to drive investor interest in PharmEasy Share:
- Strong brand recognition in India's digital healthcare market.
- Presence across online pharmacies and diagnostics as well as telehealth services.
- Large and growing healthcare market opportunity.
- Increasing adoption of digital healthcare solutions across India.
- Potential long-term value creation through a future PharmEasy IPO.
- Opportunity for investors to gain exposure through PharmEasy Unlisted Share Price before a public listing.
Company Overview
India's healthcare industry is undergoing a digital transformation, and PharmEasy is one of the key players leading the change. The company's technology platform is designed to increase the accessibility, affordability, and convenience for consumers in the healthcare industry.
PharmEasy's services go beyond medicine delivery. It also lets users book lab tests, access healthcare consultations, and buy health care products, making for a full healthcare experience under a single brand.
As one of the largest players in India's online healthcare ecosystem, the company is well positioned to benefit from increasing healthcare spending and the growing shift toward digital services.
Industry Outlook
India's healthcare industry offers significant long-term growth opportunities, with digital healthcare emerging as one of the fastest-growing segments. Rising internet penetration, increasing healthcare awareness, and changing consumer preferences are accelerating the adoption of online healthcare services.
Online pharmacies are a significant part of the healthcare ecosystem, especially since the pandemic sparked a greater shift toward digital healthcare options. The ease of ordering medicines online, booking diagnostic tests from home, and consulting doctors remotely has resulted in great demand across the sector.
Despite the expansion, digital healthcare penetration in India is still lower than in developed countries, with significant potential for expansion still to be realized. This offers a favorable opportunity for companies such as PharmEasy that are focused on building scalable healthcare platforms.
As digital healthcare adoption continues to increase, PharmEasy is expected to remain a key player in the sector, supported by its strong customer base, diversified service offerings, and established market presence as well.
Fundamentals
Financials
All values are INR Cr except per share value
| P&L Statement | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | 5728.82 | 6643.94 | 5664.29 |
| Other Income | 52.18 | 55.83 | 94.66 |
| COGS | 85.46 | 156.92 | 164.51 |
| Gross Profit | 5695.54 | 6542.85 | 5594.43 |
| Total Expense | 8247.35 | 8573.32 | 699.36 |
| EBIDTA | -2551.81 | -2030.80 | -1279.91 |
| D&A | 158.79 | 243.44 | 215.95 |
| EBIT | -2710.59 | -2274.24 | -1495.86 |
| PBT | -3983.95 | -5196.22 | -2522.85 |
| TAX | 21.73 | 15.21 | 11.54 |
| PAT | -4005.67 | -5196.22 | -2522.85 |
| Diluted EPS | -7.28 | -8.51 | -4.07 |
| Basic EPS | -7.28 | -8.51 | -4.07 |
| Total income | 5,781.00 | 6,699.77 | 5,758.95 |
ASSETS
| CURRENT ASSETS | 2022 | 2023 | 2024 |
|---|---|---|---|
| Cash and Cash Equivalents | 154.40 | 193.65 | 327.99 |
| Trade Payables | 860.85 | 905.03 | 706.21 |
| Inventory | 761.24 | 688.16 | 555.56 |
| Other Current Assets | 725.72 | 748.02 | 1886.49 |
| Total Current Assets | 2,502.21 | 2,534.86 | 3,476.25 |
| NON CURRENT ASSETS | 2022 | 2023 | 2024 |
|---|---|---|---|
| Plant Property and Equipment | 361.38 | 337.90 | 286.24 |
| Other Non Current Assets | 8534.74 | 5383.65 | 4627.17 |
| Total Non Current Assets | 8,896.12 | 5,721.55 | 4,913.41 |
| Total Assets | 11,398.33 | 8,256.41 | 8,389.66 |
|---|
| CURRENT LIABILITES | 2022 | 2023 | 2024 |
|---|---|---|---|
| TRADW Payable | 458.88 | 413.41 | 412.91 |
| Other Current Liab | 3302.73 | 1909.81 | 3089.57 |
| NON CURRENTLIABILITIES | 2022 | 2023 | 2024 |
|---|---|---|---|
| Long Term Debt | 100.07 | - | - |
| Deffered Tax Liab | 196.76 | 179.37 | 173.27 |
| Other Non Current Liab | 317.41 | 3316.93 | 2125.60 |
LIABILITIES
| EQUITY | 2022 | 2023 | 2024 |
|---|---|---|---|
| Share Capital | 614.20 | 614.20 | 624.04 |
| Other Equity | 6408.28 | 1822.69 | 1964.27 |
| Total Equity | 7,022.48 | 2,436.89 | 2,588.31 |
| Total Liabilities & Equity | 7,022.48 | 2,436.89 | 2,588.31 |
|---|
| CASH FLOW STAT | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Cash Flow from operating | - | -2589.37 | -746.59 | -61.14 |
| Cash Flow from financing | - | 8305.37 | 853.49 | 1456.83 |
| Cash Flow from investing | - | -5789.21 | -71.08 | -1260.95 |
| Net cash flow | 0.00 | -73.21 | 35.82 | 134.74 |
Revenue Growth
PAT Growth %
EPS Growth %
TOTAL ASSETS Growth %
QUICK RATIO Growth %
LONG TERM DEBT TO EQUITY RATIO Growth %
Shareholding Pattern
2026
| Name | Designation | Share % |
|---|---|---|
| Naspers Ventures B.V. | NA | 13.03% |
| MacRitchie Investment Pte. Ltd. | NA | 11.74% |
| TPG Growth V SF Markets Pte. Ltd | NA | 7.20% |
| Evermed Holdings Pte. Ltd | NA | 6.35% |
| Prasid Uno Family Trust Through Its Trustee Surbhi Singh | NA | 4.39% |
| Others | NA | 57.29% |
Events
| Name | Date | Details |
|---|---|---|
| No events available. | ||
Frequently Asked Questions
Like any other financial product or commodity, the price of unlisted shares is discovered at the intersection of demand from buyers and supply from sellers of particular unlisted shares.
The two determinants of price are dynamic factors and keep changing constantly, hence share price tends to fluctuate constantly – every day, every minute.
Upon successful completion of a deal, the unlisted shares are credited electronically directly to your standard demat account that is usually created with CDSL or NSDL (Central Depository Services Limited or National Securities Depository Limited).
The lock-in period of Purple Style Labs Limited varies depending on the category of the investor:
-
Venture capital or foreign venture capital investors are subject to lock-in period of 6 months from the date of acquisition of shares
-
For AIF investors of Category-II are not subject to any lock-in.
-
Any other investor, including retail investors, HNI or corporate investors are subject to a lock-in period of 6 months from the date of listing.
Note – The above-mentioned lock-in is for mainboard, however for SME IPO the applicable lock-in period is 1 Year.
There is no regulatory minimum limit to invest in unlisted shares. However, minimum investment size varies with the per share price. Earlier, the typical investment size often ranges between 70K – 100K, but with the growing awareness and increased participation the investment size has been down sized to 50k.
Short-Term Capital Gain tax is applicable when you sell your unlisted shares within a year from date of acquisition. Realized gain is taxable at your slab rate after consolidating in total income for the year. Hence, the rate of tax depends on your overall income for the particular financial year.
Long-Term Capital Gain taxes are applicable when you sell your unlisted shares after two years from the date of acquisition. LTCG tax is calculated on profits realized on sale of unlisted shares at 12.5%. Investors particularly retail or HNI must understand the concept clearly as it impacts strategy and tax planning.
-
You can download the NSDL or CDSL application and login into the account and check whether the shares have been credited or not.
-
Credit of Unlisted Shares/Pre-IPO shares can be checked in brokers application as well but it takes T+2 days to show the shares.
-
You would also get email confirmation of credit of shares via email
-
The value of share in unlisted space is determined in the same way as it is done in the listed market. Demand and supply decide the price of any share. If the demand is more than the supply, then the price of the share increases and vice versa.
-
When a new share is introduced in the unlisted space, the value of the company is decided upon the last funding raised by the company. If the company hasn’t raised any funding in the past, then the valuation is decided upon the fundamentals of the company.
Yes, investing in unlisted shares is legal in India, the activity is regulated and governed under the rules and guidelines laid by SEBI (Securities and Exchange Board of India). Related parties must comply with the regulations and guidelines to ensure legal and financial standards.
Investing in unlisted shares in India carries a significant and distinctive risk profile such as limited liquidity, lack of transparent pricing and regulatory oversight because unlisted shares do not trade on listed stock exchange, they are bought or sold in OTC (over the counter) market that makes vulnerable to following risks:
-
Liquidity risk, unlisted shares are difficult to buy and sell,
-
Lack of transparent pricing, as share price of pre-IPO or unl;isted company is often determined by narrative not fundamentals
-
Lack of information disclosure, unlisted companies are not mandated for disclosures like listed companies
-
Tax ambiguity, because determination of fair market value and cost of acquisition of unlisted shares is often disputed
Hence, investors should carefully examine related facts before investing in Pre-IPO or unlisted shares.